- call +1-201-465-4211
- email sales@mrinsights.biz
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Scope of the Report:
The global mRNA Cancer Vaccines and Therapeutics market is valued at 110 million USD in 2018 and is expected to reach 400 million USD by the end of 2024, growing at a CAGR of 24.3% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of mRNA Cancer Vaccines and Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the mRNA Cancer Vaccines and Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the mRNA Cancer Vaccines and Therapeutics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Market Segment by Applications, can be divided into
Infectious Disease
Cancer
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 mRNA Cancer Vaccines and Therapeutics Market Overview
1.1 Product Overview and Scope of mRNA Cancer Vaccines and Therapeutics
1.2 Classification of mRNA Cancer Vaccines and Therapeutics by Types
1.2.1 Global mRNA Cancer Vaccines and Therapeutics Revenue Comparison by Types (2019-2024)
1.2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Types in 2018
1.2.3 Adeno Carcinomas
1.2.4 Mucinous Carcinomas
1.2.5 Adenosquamous Carcinomas
1.3 Global mRNA Cancer Vaccines and Therapeutics Market by Application
1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Other
1.4 Global mRNA Cancer Vaccines and Therapeutics Market by Regions
1.4.1 Global mRNA Cancer Vaccines and Therapeutics Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) mRNA Cancer Vaccines and Therapeutics Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) mRNA Cancer Vaccines and Therapeutics Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) mRNA Cancer Vaccines and Therapeutics Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) mRNA Cancer Vaccines and Therapeutics Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) mRNA Cancer Vaccines and Therapeutics Status and Prospect (2014-2024)
1.5 Global Market Size of mRNA Cancer Vaccines and Therapeutics (2014-2024)
2 Manufacturers Profiles
2.1 Moderna Therapeutics
2.1.1 Business Overview
2.1.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.2 CureVac
2.2.1 Business Overview
2.2.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.3 Translate Bio
2.3.1 Business Overview
2.3.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.4 BioNTech
2.4.1 Business Overview
2.4.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.5 Sangamo Therapeutics
2.5.1 Business Overview
2.5.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.6 Argos Therapeutics
2.6.1 Business Overview
2.6.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.7 In-Cell-Art
2.7.1 Business Overview
2.7.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.8 eTheRNA
2.8.1 Business Overview
2.8.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.9 Ethris
2.9.1 Business Overview
2.9.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.10 Tiba Biotechnology
2.10.1 Business Overview
2.10.2 mRNA Cancer Vaccines and Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
3 Global mRNA Cancer Vaccines and Therapeutics Market Competition, by Players
3.1 Global mRNA Cancer Vaccines and Therapeutics Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 mRNA Cancer Vaccines and Therapeutics Players Market Share
3.2.2 Top 10 mRNA Cancer Vaccines and Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global mRNA Cancer Vaccines and Therapeutics Market Size by Regions
4.1 Global mRNA Cancer Vaccines and Therapeutics Revenue and Market Share by Regions
4.2 North America mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
4.3 Europe mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
4.5 South America mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
5 North America mRNA Cancer Vaccines and Therapeutics Revenue by Countries
5.1 North America mRNA Cancer Vaccines and Therapeutics Revenue by Countries (2014-2019)
5.2 USA mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
5.3 Canada mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
5.4 Mexico mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
6 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Countries
6.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Countries (2014-2019)
6.2 Germany mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
6.3 UK mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
6.4 France mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
6.5 Russia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
6.6 Italy mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
7 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Countries
7.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Countries (2014-2019)
7.2 China mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
7.3 Japan mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
7.4 Korea mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
7.5 India mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
8 South America mRNA Cancer Vaccines and Therapeutics Revenue by Countries
8.1 South America mRNA Cancer Vaccines and Therapeutics Revenue by Countries (2014-2019)
8.2 Brazil mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
8.3 Argentina mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
8.4 Colombia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue mRNA Cancer Vaccines and Therapeutics by Countries
9.1 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Countries (2014-2019)
9.2 Saudi Arabia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
9.3 UAE mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
9.4 Egypt mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
9.5 Nigeria mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
9.6 South Africa mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2014-2019)
10 Global mRNA Cancer Vaccines and Therapeutics Market Segment by Type
10.1 Global mRNA Cancer Vaccines and Therapeutics Revenue and Market Share by Type (2014-2019)
10.2 Global mRNA Cancer Vaccines and Therapeutics Market Forecast by Type (2019-2024)
10.3 Adeno Carcinomas Revenue Growth Rate (2014-2024)
10.4 Mucinous Carcinomas Revenue Growth Rate (2014-2024)
10.5 Adenosquamous Carcinomas Revenue Growth Rate (2014-2024)
11 Global mRNA Cancer Vaccines and Therapeutics Market Segment by Application
11.1 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2014-2019)
11.2 mRNA Cancer Vaccines and Therapeutics Market Forecast by Application (2019-2024)
11.3 Infectious Disease Revenue Growth (2014-2019)
11.4 Cancer Revenue Growth (2014-2019)
11.5 Other Revenue Growth (2014-2019)
12 Global mRNA Cancer Vaccines and Therapeutics Market Size Forecast (2019-2024)
12.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Forecast (2019-2024)
12.2 Global mRNA Cancer Vaccines and Therapeutics Market Forecast by Regions (2019-2024)
12.3 North America mRNA Cancer Vaccines and Therapeutics Revenue Market Forecast (2019-2024)
12.4 Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Forecast (2019-2024)
12.6 South America mRNA Cancer Vaccines and Therapeutics Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure mRNA Cancer Vaccines and Therapeutics Picture
Table Product Specifications of mRNA Cancer Vaccines and Therapeutics
Table Global mRNA Cancer Vaccines and Therapeutic
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
